logo-loader

Aptose Biosciences gains after FDA greenlights Phase 1 trial for blood cancer drug CG-806

Last updated: 08:50 25 Mar 2019 EDT, First published: 08:30 25 Mar 2019 EDT

cancer cells
Aptose is a clinical-stage biotech company specializing in oncology

Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) told investors Monday that the US Food and Drug Administration is giving the go-ahead for the clinical-stage biotech to kick off a Phase 1 clinical trial to evaluate its drug CG-806 for the treatment of chronic lymphocytic leukemia or non-Hodgkin lymphomas.

Aptose is now set to start its Phase 1 trial of CG-806 in the second quarter of this year for patients with relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin lymphomas who have failed to respond to standard therapies.

READ: Aptose Biosciences reaches China distribution deal for CG-806 with South Korea's CrystalGenomics

“We are pleased that the FDA has allowed Aptose to perform clinical trials with CG-806, our first-in-class pan-FLT3/pan-BTK inhibitor,” said Dr. William Rice, Aptose’s CEO. “CG-806 has demonstrated a favorable safety profile and compelling durable tumor elimination in animal models of cancer, and we look forward to advancing it into human clinical testing.”

After reviewing the initial data from this trial, Aptose plans to broaden its program to include patients with relapsed or refractory acute myeloid leukemia as well as myelodysplastic syndromes in a separate Phase 1 trial.

CG-806 is a small molecule that is being developed for the treatment of acute myeloid leukemia, B-cell malignancies and additional blood cancers.

Headquartered in San Diego, California and Toronto, Canada, Aptose is a clinical-stage biotech company specializing in oncology, but with a focus on hematology.

Aptose shares slipped US$0.09 to hit $2.22 in afternoon trade Monday after trading higher earlier in the day.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

-- This story is updated to reflect latest share price movement --

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 37 minutes ago